Recently, a new study confirmed that SMI can inhibit the function and expression of P-gp through the MAPK/NF-κB signaling pathway and enhance the sensitivity of breast cancer cells to chemotherapy [25]. This evidence concerns the gene NFKB1 and breast cancer.